Abstract
Preoperative intraperitoneal (IP) chemotherapy was performed in 23 patients with gastric malignancies to inhibit peritoneal recurrence. Cis-diamminedichloroplatinum (CDDP) and mitomycin C (MMC) were administered intraperitoneally 3 days prior to surgery, at which time a very viscid peritoneum and mucinous intraperitoneal fluid were found in 100% and 83% of the patients, respectively. Inflammatory changes were microscopically observed in the subserosal layer of the resected stomachs and in the intraperitoneal fluid, but degenerative changes characteristic of cancer cells could not be seen. The 3-year survival rate of the stage III patients was 55.6%, and peritoneal recurrence was found in three of six patients with recurrence. Extensive adhesions were found in eight patients (34.8%) as a delayed peritoneal complication, and chronic bowel obstruction resulting from the adhesion developed in five patients (21.7%). Thus, we conclude that the administration of this IP chemotherapy demonstrated no definite antitumor effects or survival benefits, but was frequently associated with delayed peritoneal complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11
Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Int Med 97:845–851
Zylberberg B, Ravina JH, Salat-Baroux J, Madelenat P, Zarca D, Dormont D (1990) Chemotherapy by the intravenous and intraperitoneal routes combined in ovarian cancer. Gynecol Oncol 36:271–276
Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr (1983) Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 67:235–238
Markman M (1985) Intracavitary chemotherapy for malignant disease confined to body cavities. West J Med 142:364–368
Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE (1985) Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98:414–422
Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K, Sakakura C (1992) Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339:629–631
Iwanaga T, Koyama H, Furukawa H, Taniguchi H, Wada A, Tateishi R (1978) Mechanisms of late recurrence after radical surgery for gastric carcinoma. Am J Surg 135:637–640
Fujimoto S, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N, Takamizawa H (1988) Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 208:36–41
Fujimura T, Yonemura Y, Fushida S, Urade M, Takegawa S, Kamata T, Sugiyama K, Hasegawa H, Katayama K, Miwa K, Miyazaki I (1990) Continuous hyperthermic peritoneal perfusion for the treatment of peritoneal dissemination in gastric cancers and subsequent second-look operation. Cancer 65:65–71
Japanese Research Society for Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathlogy. Part I. Clinical classification. Jpn J Surg 11:127–139
The Japanese Research Society Committee on Histological Classification of Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. Part II. Histological classification of gastric cancer. Jpn J Surg 11:140–145
Fujita H (1974) In vivo distribution of anticancer agents — Methods of Assay (in Japanese). Gan to Kagakuryoho (Jpn J Cancer Chemother) 1:497–503
Bannister SJ, Chang Y, Sternson LA, Repta AJ (1978) Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichloro diammineplatinum (II). Clin Chem 24:877–880
Nakajima T (1990) Adjuvant chemotherapy for gastric cancer in Japan: Present status and suggestions for rational clinical trials. Jpn J Clin Oncol 20:30–42
Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius VK (1984) Cisplatin. An active drug in the treatment of disseminated gastric cancer. Cancer 53:18–22
Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M Jr, Chapman D, Saigo P, Lewis JL Jr (1989) Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 7:1327–1332
Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullem L (1990) Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 8:2054–2061
Kano T, Kumashiro R, Masuda H, Tamada R, Inokuchi K (1983) Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection. Jpn J Surg 13:112–116
Akiyoshi T, Kawaguchi M, Arinaga S, Miyazaki S, Koba F, Wada T, Tsuji H (1984) Combination chemoimmunotherapy for advanced gastric carcinoma. Jpn J Surg 14:185–190
Philips FS, Schwartz HS, Sternberg SS (1960) Pharmacology of mitomycin C. I. Toxicity and pathologic effects. Cancer Res 20:1354–1361
Pretorius RG, Petrilli ES, Kean C, Ford LC, Hoeschele JD, Lagasse LD (1981) Comparison of the iv and ip routes of administration of cisplatin in dogs. Cancer Treat Rep 65:1055–1062
Zakris EL, Dewhirst MW, Riviere JE, Hoopes PJ, Page RL, Oleson JR (1987) Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 5:1613–1620
Markman M, Cleary S, Howell SB, Lucas WE (1986) Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg Gynecol Obstet 162:445–448
Gianola FJ, Sugarbaker PH, Barofsky I, White DE, Meyers CE (1986) Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Am J Clin Oncol 9:403–410
Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE (1982) Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4256–4269
Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB (1991) A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol 9:649–657
Markman M, Kelsen D (1989) Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma. Reg Cancer Treat 2:49–53
van Oosterom AT, Jol C, de Bruijn EA, Pauwels EKJ, Kuin C, Trimbos JB, Nooy MA, Tjaden UR (1987) Intraperitoneal chemotherapy with mitomycin C in patients with resistant ovarian cancer. In: Taguchi T, Andrysek O (eds) New trends in cancer chemotherapy with mitomycin C. Excerpta Medica, Tokyo, pp 192–200
Rodgers KE, Girgis W, diZerega GS (1992) Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antineoplastic agents. Cancer Chemother Pharmacol 29:248–251
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Adachi, W., Koike, S., Rafique, M. et al. Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications. Surg Today 25, 396–403 (1995). https://doi.org/10.1007/BF00311815
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00311815